TERT promoter mutations in thyroid cancer: A report from a Middle Eastern population

Endocrine-Related Cancer

Volumn 22, Issue 6, 2015, Pages 901-908

  Qasem, Ebtesam ^a   Murugan, Avaniyapuram Kannan ^a   Al Hindi, Hindi ^a   Xing, Mingzhao ^b   Almohanna, Mai ^a   Alswailem, Meshael ^a   Alzahrani, Ali S ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Carcinoma; Thyroid

Indexed keywords

PARAFFIN; TELOMERASE REVERSE TRANSCRIPTASE; B RAF KINASE; BRAF PROTEIN, HUMAN; DNA; RADIOACTIVE IODINE; TELOMERASE; TERT PROTEIN, HUMAN; TUMOR PROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER STAGING; CHILD; CONVENTIONAL PAPILLARY THYROID CANCER; DISEASE DURATION; DNA ISOLATION; ETHNIC GROUP; FEMALE; FOLLICULAR THYROID CANCER; FOLLICULAR VARIANT PAPILLARY THYROID CANCER; FOLLOW UP; GENE MUTATION; GENE REPLICATION; GENE SEQUENCE; HISTOPATHOLOGY; HUMAN; HURTHLE CELL THYROID CANCER; MAJOR CLINICAL STUDY; MALE; MIDDLE EAST; POLYMERASE CHAIN REACTION; POORLY DIFFERENTIATED THYROID CANCER; PREVALENCE; PROMOTER REGION; RECURRENT DISEASE; TALL CELL VARIANT PAPILLARY THYROID CANCER; THYROID ADENOMA; THYROID CANCER; TUMOR VOLUME; ADENOCARCINOMA, FOLLICULAR; ADENOMA; ADENOMA, OXYPHILIC; AGE; ARAB; CARCINOMA, PAPILLARY; EPIDEMIOLOGY; ETHNOLOGY; GENETICS; MIDDLE AGED; MISSENSE MUTATION; MULTIMODALITY CANCER THERAPY; PATHOLOGY; POINT MUTATION; SAUDI ARABIA; THYROID NEOPLASMS; THYROIDECTOMY; TREATMENT OUTCOME; TUMOR INVASION; YOUNG ADULT;

ADENOCARCINOMA, FOLLICULAR; ADENOMA; ADENOMA, OXYPHILIC; ADOLESCENT; ADULT; AGE FACTORS; AGED; ARABS; CARCINOMA, PAPILLARY; CHILD; COMBINED MODALITY THERAPY; DNA, NEOPLASM; ETHNIC GROUPS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; MUTATION, MISSENSE; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEOPLASM STAGING; POINT MUTATION; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS B-RAF; RECURRENCE; SAUDI ARABIA; TELOMERASE; THYROID NEOPLASMS; THYROIDECTOMY; TREATMENT OUTCOME; TUMOR BURDEN; YOUNG ADULT;

EID: 84948142133     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-15-0396     Document Type: Article

References (30)

1. Agrawal N, Akbani R, Aksoy BA, Ally A, Arachchi H, Asa SL, Auman JT, Balasundaram M, Balu S, Baylin SB et al. 2014 Integrated genomic characterization of papillary thyroid carcinoma. Cell 159 676-690. (doi:10.1016/j.cell.2014.09.050)
2. Antonello ZA & Nucera C 2014 Orthotopic mouse models for the preclinical and translational study of targeted therapies against metastatic human thyroid carcinoma with BRAF(V600E) or wild-type BRAF. Oncogene 33 5397-5404. (doi:10.1038/onc.2013.544)
3. Blackburn EH 2005 Telomeres and telomerase: their mechanisms of action and the effects of altering their functions. FEBS Letters 579 859-862. (doi:10.1016/j.febslet.2004.11.036)
4. Chindris AM, Casler JD, Bernet VJ, Rivera M, Thomas C, Kachergus JM, Necela BM, Hay ID, Westphal SA, Grant CS et al. 2015 Clinical and molecular features of Hurthle cell carcinoma of the thyroid. Journal of Clinical Endocrinology and Metabolism 100 55-62. (doi:10.1210/jc.2014-1634)
5. Enewold L, Zhu K, Ron E, Marrogi AJ, Stojadinovic A, Peoples GE & Devesa SS 2009 Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005. Cancer Epidemiology, Biomarkers & Prevention 18 784-791. (doi:10.1158/ 1055-9965.EPI-08-0960)
6. Fredriksson NJ, Ny L, Nilsson JA & Larsson E 2014 Systematic analysis of noncoding somatic mutations and gene expression alterations across 14 tumor types. Nature Genetics 46 1258-1263. (doi:10.1038/ ng.3141)
7. Gandolfi G, Ragazzi M, Frasoldati A, Piana S, Ciarrocchi A & Sancisi V 2015 TERT promoter mutations are associated with distant metastases in papillary thyroid carcinoma. European Journal of Endocrinology/European Federation of Endocrine Societies 172 403-413. (doi:10.1530/EJE-14-0837)
8. Horn S, Figl A, Rachakonda PS, Fischer C, Sucker A, Gast A, Kadel S, Moll I, Nagore E, Hemminki K et al. 2013 TERT promoter mutations in familial and sporadic melanoma. Science 339 959-961. (doi:10.1126/science. 1230062)
9. Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L & Garraway LA 2013 Highly recurrent TERT promoter mutations in human melanoma. Science 339 957-959. (doi:10.1126/science.1229259)
10. Jemal A, Bray F, Center MM, Ferlay J, Ward E & Forman D 2011 Global cancer statistics. CA: A Cancer Journal for Clinicians 61 69-90. (doi:10.3322/caac.20107)
11. Jemal A, Simard EP, Dorell C, Noone AM, Markowitz LE, Kohler B, Eheman C, Saraiya M, Bandi P, Saslow D et al. 2013 Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus (HPV)-associated cancers and HPV vaccination coverage levels. Journal of the National Cancer Institute 105 175-201. (doi:10.1093/jnci/djs491)
12. Jung CK, Little MP, Lubin JH, Brenner AV, Wells SA Jr, Sigurdson AJ & Nikiforov YE 2014 The increase in thyroid cancer incidence during the last four decades is accompanied by a high frequency of BRAF mutations and a sharp increase in RAS mutations. Journal of Clinical Endocrinology and Metabolism 99 E276-E285. (doi:10.1210/ jc.2013-2503)
13. Landa I, Ganly I, Chan TA, Mitsutake N, Matsuse M, Ibrahimpasic T, Ghossein RA & Fagin JA 2013 Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. Journal of Clinical Endocrinology and Metabolism 98 E1562-E1566. (doi:10.1210/jc.2013-2383)
14. Liu R & Xing M 2014 Diagnostic and prognostic TERT promoter mutations in thyroid fine-needle aspiration biopsy. Endocrine-Related Cancer 21 825-830. (doi:10.1530/ERC-14-0359)
15. Liu X, Bishop J, Shan Y, Pai S, Liu D, Murugan AK, Sun H, El-Naggar AK & Xing M 2013 Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocrine-Related Cancer 20 603-610. (doi:10.1530/ ERC-13-0210)
16. Liu X, Qu S, Liu R, Sheng C, Shi X, Zhu G, Murugan AK, Guan H, Yu H, Wang Y et al. 2014a TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer. Journal of Clinical Endocrinology and Metabolism 99 E1130-E1136. (doi:10.1210/jc.2013-4048)
17. Liu T, Wang N, Cao J, Sofiadis A, Dinets A, Zedenius J, Larsson C & Xu D 2014b The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas. Oncogene 33 4978-4984. (doi:10.1038/onc.2013.446)
18. Melo M, da Rocha AG, Vinagre J, Batista R, Peixoto J, Tavares C, Celestino R, Almeida A, Salgado C, Eloy C et al. 2014 TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas. Journal of Clinical Endocrinology and Metabolism 99 E754-E765. (doi:10.1210/jc.2013-3734)
19. Mocellin S, Pooley KA & Nitti D 2013 Telomerase and the search for the end of cancer. Trends in Molecular Medicine 19 125-133. (doi:10.1016/ j.molmed.2012.11.006)
20. Muzza M, Colombo C, Rossi S, Tosi D, Cirello V, Perrino M, De Leo S, Magnani E, Pignatti E, Vigo B et al. 2015 Telomerase in differentiated thyroid cancer: promoter mutations, expression and localization. Molecular and Cellular Endocrinology 399 288-295. (doi:10.1016/j.mce. 2014.10.019)
21. Ngeow J & Eng C 2014 TERT and BRAF in thyroid cancer: teaming up for trouble. Journal of Clinical Oncology 32 2683-2684. (doi:10.1200/JCO. 2014.56.5614)
22. Sadow PM, Priolo C, Nanni S, Karreth FA, Duquette M, Martinelli R, Husain A, Clohessy J, Kutzner H, Mentzel T et al. 2014 Role of BRAFV600E in the first preclinical model of multifocal infiltrating myopericytoma development and microenvironment. Journal of the National Cancer Institute 106 dju182. (doi:10.1093/jnci/dju182)
23. Shi X, Liu R, Qu S, Zhu G, Bishop J, Liu X, Sun H, Shan Z, Wang E, Luo Y et al. 2015 Association of TERT promoter mutation 1, 295, 228 COT with BRAF V600E mutation, older patient age, and distant metastasis in anaplastic thyroid cancer. Journal of Clinical Endocrinology and Metabolism 100 E632-E637. (doi:10.1210/jc.2014-3606)
24. Smekalova EM, Shubernetskaya OS, Zvereva MI, Gromenko EV, Rubtsova MP & Dontsova OA 2012 Telomerase RNA biosynthesis and processing. Biochemistry 77 1120-1128.
25. Vinagre J, Almeida A, Populo H, Batista R, Lyra J, Pinto V, Coelho R, Celestino R, Prazeres H, Lima L et al. 2013 Frequency of TERT promoter mutations in human cancers. Nature Communications 4 2185. (doi:10.1038/ncomms3185)
26. Vinagre J, Pinto V, Celestino R, Reis M, Populo H, Boaventura P, Melo M, Catarino T, Lima J, Lopes JM et al. 2014 Telomerase promoter mutations in cancer: an emerging molecular biomarker? Virchows Archiv 465 119-133. (doi:10.1007/s00428-014-1608-4)
27. Wang N, Liu T, Sofiadis A, Juhlin CC, Zedenius J, Hoog A, Larsson C & Xu D 2014a TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA. Cancer 120 2965-2979. (doi:10.1002/cncr.28800)
28. Wang N, Xu D, Sofiadis A, Hoog A, Vukojevic V, Backdahl M, Zedenius J & Larsson C 2014b Telomerase-dependent and independent telomere maintenance and its clinical implications in medullary thyroid carcinoma. Journal of Clinical Endocrinology and Metabolism 99 E1571-E1579. (doi:10.1210/jc.2014-1158)
29. Xing M 2013 Molecular pathogenesis and mechanisms of thyroid cancer. Nature Reviews. Cancer 13 184-199. (doi:10.1038/nrc3431)
30. Xing M, Liu R, Liu X, Murugan AK, Zhu G, Zeiger MA, Pai S & Bishop J 2014 BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. Journal of Clinical Oncology 32 2718-2726. (doi:10.1200/JCO.2014.55.5094)